Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | GGT1 | P19440 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12683553 | 1.00 | MME (0.58) | MMEACETSHRSMN1; SMN2MEN1 | |
| SCHEMBL164831 | 1.00 | MME (0.58) | MMEACETSHRSMN1; SMN2MEN1 | |
| SCHEMBL21837703 | 0.89 | GGT1 (0.52) | MMEACETSHRSMN1; SMN2KMT2A | |
| SCHEMBL21837706 | 0.89 | GGT1 (0.52) | MMEACETSHRSMN1; SMN2KMT2A | |
| SCHEMBL6535553 | 0.89 | MME (0.49) | MMEACETSHRSMN1; SMN2MEN1 | |
| SCHEMBL2523776 | 0.88 | GGT1 (0.51) | MMEKMT2AHPGDGGT1ALDH1A1 | |
| SCHEMBL24233257 | 0.87 | TSHR (0.51) | MMEACETSHRSMN1; SMN2MEN1 | |
| SCHEMBL16509240 | 0.87 | TSHR (0.51) | MMEACETSHRSMN1; SMN2MEN1 | |
| SCHEMBL13227756 | 0.87 | TSHR (0.51) | MMEACETSHRSMN1; SMN2MEN1 | |
| SCHEMBL22444710 | 0.86 | MME (0.48) | MMEACETSHRSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7070969-B1 | Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-07-04 | — | — | US | claimed |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-05-21 | — | — | US | disclosed |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2026-05-07 | — | — | US | disclosed |
| WO-2026085582-A1 | PROTEIN CAGES | THE UNIVERSITY OF SYDNEY (AU) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109870-A1 | PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-04-23 | — | — | US | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12605425-B2 | TNF muteins and uses thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-04-21 | — | — | US | disclosed |
| EP-4710935-A2 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | Aravax Pty Ltd (AU) | 2026-03-18 | — | — | EP | disclosed |
| US-12576191-B2 | Method of inducing cardiomyocytes proliferation and treating heart diseases | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2026-03-17 | — | — | US | disclosed |
| WO-1997023629-A1 | A NOVEL RECEPTOR-TYPE TYROSINE KINASE AND USE THEREOF | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997023501-A1 | THERAPEUTIC COMPOSITIONS | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997016202-A1 | CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997015663-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997012037-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-04-03 | — | — | WO | disclosed |
| WO-1997005257-A1 | PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
| WO-1997004091-A1 | NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-02-06 | — | — | WO | disclosed |
| EP-0672049-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994011388-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | PTH1R, FGF23, PTMS | MME 971/4885ACE 842/4885TSHR 39/4885 |
| US-12605425-B2 | TNF muteins and uses thereof | TNFRSF1A, TNF, TNFSF11 | MME 629/4885ACE 4286/4885TSHR 713/4885 |
| US-20260109870-A1 | PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME | NONO, NGLY1, PTMS | MME 1046/4885ACE 2080/4885TSHR 2542/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | MME 51/4885ACE 108/4885TSHR 1510/4885 |
| US-12576191-B2 | Method of inducing cardiomyocytes proliferation and treating heart diseases | MYLK2, TNNI3, MYL6 | MME 1483/4885ACE 3572/4885TSHR 305/4885 |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | CTSL, CPA4, ACE2 | MME 159/4885ACE 11/4885TSHR 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.